Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Leukemia, chronic lymphocytic (CLL)
Stage/Subtype:  stage I chronic lymphocytic leukemia
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 45 for your search:
Start Over
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients with Lymphoma
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 0508M72589, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR100955, NCI-2013-02262, 2012-004225-24, PCI-32765CAN3001, NCT01804686
Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Phase: Phase III
Type: Treatment
Age: 65 and over
Trial IDs: GS-US-312-0118, NCI-2015-01760, 2013-004551-20, NCT01980875
A Study to Compare the Efficacy and Safety of Obinutuzumab + GDC-0199 Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: BO25323, NCI-2015-00926, 2014-001810-24, NCT02242942
Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ACE-CL-007, NCI-2015-02261, NCT02475681
Allogeneic Stem Cell Transplant for Chronic Lymphocytic Leukemia (CLL)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 2012-0249, NCI-2012-01248, NCT01629511
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
IPI-145 with Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 14-193, NCI-2014-01565, NCT02158091
Lenalidomide and Combination Chemotherapy in Treating Patients with MYC-Associated B-Cell Lymphomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-1406, NCI-2014-01581, IRB13-1406, IRB13-1406-CR001, NCT02213913
Obinutuzumab and High-Dose Methylprednisolone in Treating Patients with Chronic Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UCSD GA101+HDMP, NCI-2014-01950, 140396, GA101-HDMP, NCT02229422
Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: DV3-LYM-01, NCI-2014-02214, NCT02266147
Ibrutinib and Obinutuzumab in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and over
Trial IDs: GA101 + Ibrutinib, NCI-2015-02052, 141106, NCT02315768
ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-LY-005, NCI-2015-01019, NCT02362035
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: 16349, NCI-2014-02647, 2012-002602-52, NCT01660451
Rituximab and Everolimus in Treating Patients with B-Cell Lymphoma, Gray Zone Lymphoma, or Hodgkin Lymphoma Receiving High-Dose Therapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: J1228, NCI-2012-02757, CIR00004190, CRAD001NUS157T, NA_00067315, NCT01665768
Bendamustine Hydrochloride and Rituximab Followed by Rituximab and Lenalidomide in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: HO11414, NCI-2013-00485, 2012-0638, 2012-0638-CP008, 2012-0638-CR003, ML28201, RV-CLL/ -PI-0689, NCT01754857
Treatment for Advanced B-Cell Lymphoma
Phase: Phase II
Type: Treatment
Age: 3 to 31
Trial IDs: NYMC-157, NCI-2015-01702, L 10,753, NCT01859819
Safety Study of Cord Blood Units for Stem Cell Transplants
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 130116, NCI-2014-01832, 13-H-0116, NCT01861093
Lenalidomide in Improving Hypogammaglobulinemia and Impaired Response to Vaccinations in Patients with Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0371, NCI-2014-01058, RV-CL-CLL-PI-002544, NCT01924169
Start Over